Drug Approval | November 24, 2023
Lupin receives tentative approval from USFDA for Canagliflozin Tablets
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
This product will be manufactured at Lupin’s Pithampur facility in India
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans
She joins Enveda from Gilead Sciences
The aim is to provide further insights into patients' lives in the effort to deliver better outcomes for people with psoriatic arthritis (PsA)
The icare4u program features a dedicated website, with comprehensive information about the diseases, videos with medical experts, and a social media community for patients and caregivers on Facebook and YouTube
Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV
Subscribe To Our Newsletter & Stay Updated
